Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?

Sean G. Kelly*, Mary Clare Masters, Babafemi O. Taiwo

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


With the second-generation integrase inhibitors (dolutegravir and bictegravir) extending the attributes of earlier integrase inhibitors, three-drug regimens containing integrase inhibitors plus two nucleos(t)ide reverse transcriptase inhibitors are now widely recommended for first-line (initial) treatment of human immunodeficiency virus-1 infection. Led by dolutegravir plus lamivudine, two-drug therapy is emerging as a way to reduce antiretroviral therapy cost and adverse effects without compromising treatment options should virologic failure occur. Initial two-drug therapy has limitations, including the relative incompatibility with the coemerging concept of same-day antiretroviral therapy initiation.

Original languageEnglish (US)
Pages (from-to)681-692
Number of pages12
JournalInfectious disease clinics of North America
Issue number3
StatePublished - Sep 2019


  • Bictegravir
  • Dolutegravir
  • Dual therapy
  • Integrase stand transfer inhibitors
  • Rapid start

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?'. Together they form a unique fingerprint.

Cite this